Xenon Pharmaceuticals Inc

CEO Mortimer Ian’s March 2026 trades reveal a bold 75,000‑share buy at $8.40, a steep discount amid heavy sales near $60, suggesting strong insider confidence and a possible upside rally for Xenon’s Azetukalner drug.

CEO Mortimer Ian’s March 2026 insider trades reveal disciplined Rule 10b‑5‑1 buying at low prices and strategic selling as Xenon’s Phase‑III epilepsy drug gains traction, offering investors insights into long‑term confidence and liquidity strategy.